OCULAR TOXICITY OF 2',3'-DIDEOXYINOSINE

2 '，3'-二脱氧肌苷（ddI），一种具有抗逆转录病毒活性的嘌呤类似物 目前用于治疗艾滋病患者（获得性免疫缺陷 综合征），正在临床上用于治疗成人和儿童 国家卫生研究院的实验方案。 这样做的目的 研究是前瞻性地随访接受ddI治疗的患者， 继发于药物毒性的眼部并发症的发生。 九十- 五名有症状的儿童（CDC P-2级）艾滋病毒（人类免疫 在I/II期研究中招募了100名受试者，以评估 ddI的安全性和抗逆转录病毒活性。 五个孩子发展 ddI治疗期间视网膜色素上皮的周边萎缩。 两名患有最严重视网膜萎缩的儿童参加了 在研究的最高剂量水平（540 mg/m2/天）下进行研究。 电- 三名视网膜毒性患者中有一名眼电图异常 谁可以测试。 一组75名接受ddI治疗的成年人正在接受 随后进行定期眼底检查和眼电图检查。 在过去的一年中，在一名成人中发现了类似的视网膜病变 患者接受ddI治疗。

2',3'-Dideoxyinosine (ddI), a purine analog with antiretroviral activity currently used to treat patients with AIDS (acquired immunodeficiency syndrome), is being used to treat both adults and children in clinical protocols at the National Institutes of Health. The purpose of this study is to follow prospectively patients treated with ddI for the development of ocular complications secondary to drug toxicity. Ninety- five children with symptomatic (CDC class P-2) HIV (human immune deficiency virus) infection were enrolled in a phase I/II study to assess the safety and antiretroviral activity of ddI. Five children developed peripheral atrophy of the retinal pigment epithelium during ddI therapy. The tow children with the most severe retinal atrophy were enrolled in the study at the highest dose level studied (540 mg/m2/day). Electro- oculograms were abnormal in one of three patients with retinal toxicity who could be tested. A group of 75 adults treated with ddI are being followed with periodic fundus examinations and electro-oculograms. During the past year similar retinal lesions were found in one adult patient treated with ddI.